http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020153800-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7b72691b61448140b9a080282c2ccf0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a74935159a0a871dd85e00c138f7fe6b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2020-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_628fe71cb1acfb823e98299101e19b14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a4c9071b4e238dea86551c019e5bbb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4b7e2a23f6e5796f71e9c01e18575ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f01045458613f8d400e2acc6ed3fe4d |
| publicationDate | 2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020153800-A2 |
| titleOfInvention | Composition for preventing or treating triple negative breast cancer, containing tumor infiltrating lymphocytes as active ingredient |
| abstract | The present invention relates to a composition for preventing or treating triple negative breast cancer, containing tumor infiltrating lymphocytes as an active ingredient. According to the present invention, tumor infiltrating lymphocytes isolated from triple negative breast cancer tissues react with tumor cells cultured from a corresponding patient and with tumor cells in a patient-derived xenograft model so as to induce the apoptosis of tumor cell and significantly inhibit tumor growth, and exhibit anti-cancer effects by selectively acting on only a corresponding tumor. Therefore, tumor infiltrating lymphocytes having these effects can be effectively used as a pharmaceutical composition for preventing or treating triple negative breast cancer, a composition for cellular immunotherapy, and the like. |
| priorityDate | 2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.